STIKO recommends Nuvaxovid as a booster among adults aged 18 and older that have product-specific medical contraindications to mRNA COVID-19 vaccines or request Nuvaxovid after appropriate consultation. STIKO specifies that Nuvaxovid can be administered at intervals of at least six months after a previous immunological event (infection or vaccination). STIKO also recommends Nuvaxovid for off-label use as a booster in adolescents aged 12 through 17 that have product-specific medical contraindications for mRNA COVID-19 vaccines.
Nuvaxovid's breadth of immune response following boosting has been demonstrated in a number of trials including
The trade name Nuvaxovid has not yet been approved by the
Contact:
Tel: (240) 268-2022
Email: us at ir@novavax.com
(C) 2022 Electronic News Publishing, source